Quarterly Update: December 2025 Highlights

As the days grow shorter and colder, the season has been anything but quiet. This quarter has been about hard work - in our labs and out on the road - as a busy run of conferences, a wave of new business and collaborations, and a landmark first publication with a major pharma partner all came together at once. It's been one of our most eventful periods yet. Here's a round-up of what we've been up to.

1. Our First Peer-Reviewed Publication with AstraZeneca

We're incredibly proud to share that our collaborative study with AstraZeneca has been published - a genuine milestone for Nanovery and for Nucleic Acid Nanorobotics as a whole. It's the first time our platform has been shown in the peer-reviewed literature, alongside a global pharma partner, to perform pharmacokinetic bioanalysis of antisense oligonucleotides directly in plasma.

What makes the result meaningful is its simplicity. As ASO and siRNA pipelines expand, bioanalysis has increasingly become a bottleneck: the established approaches tend to be intricate, labour-intensive, and dependent on specialist expertise. Our NAN assay takes a different route - a streamlined two-step workflow with no extraction steps and no enzymes, built on a programmable molecular interaction that produces a fluorescent readout in proportion to ASO concentration. The study demonstrates the sensitivity, precision, and accuracy needed across the PK range, and - importantly - the assay was transferred to AstraZeneca's own laboratory, where their team independently qualified its performance against key bioanalytical standards.

For our partners, this is the clearest signal yet of what the platform can do in real-world hands: a method that travels, that a pharma team can run themselves, and that stands up to independent scrutiny.

You can access the publication here: Nucleic acid nanorobot assay for accurate and simplified ASO quantification in mouse plasma

2. Oligonucleotide Therapeutics Society (OTS) Annual Meeting, Budapest

Estela and Alex represented Nanovery at the OTS Annual Meeting in Budapest - the premier global gathering of the oligonucleotide community. It's a genuinely cross-disciplinary forum, drawing together chemistry, delivery, biology, immunology, and clinical medicine, with over 900 participants from 25 countries and more than 400 institutions across four days of sessions.

For a field-shaping meeting like this, the value is as much in the conversations between talks as in the science on stage. It's where new collaborations start, and where we get to test how our thinking maps onto the community's most pressing challenges as therapies move from lab to clinic.

3. BIO-Europe, Vienna

Jurek and Estela were in Vienna for BIO-Europe, one of the largest partnering events in the industry. With a packed schedule of meetings across a broad range of relevant companies, it was an intensive and productive few days of building relationships and scoping where we can help. The conference also served up a memorable networking dinner at the Hofburg, Vienna's grand baroque palace - a fitting backdrop for the kind of conversations that turn into partnerships.

4. BioTools Innovator Capstone, San Diego

Jurek travelled to San Diego for the capstone event of the BioTools Innovator programme. The panel discussions were excellent, and the calibre of the room was high throughout - our only regret is that it was a single day, because we'd happily have spent longer with that crowd. We made good use of the wider trip too, meeting local companies across the spectrum from small biotechs to large pharma. Those conversations went well, and it looks like several new collaborations will grow out of them.

5. European Bioanalysis Forum (EBF)

Roma represented Nanovery at the European Bioanalysis Forum, held under the fitting motto "Fearless Science Driven by Curiosity – Guided by Data." Roma reconnected with existing pharma collaborators and met a number of new potential partners, including large CROs who expressed real interest in working with us. We're looking forward to continuing those discussions and seeing where they lead.

Looking Ahead

If this quarter had a through-line, it was momentum: a first major publication behind us and a growing set of collaborations ahead. Into the new year, our priority stays exactly where it's always been - delivering on our promise to build the best bioanalysis platform for oligonucleotide therapeutics.

If you're working with ASOs, siRNA, or emerging oligonucleotide modalities and want simpler, more adaptable bioanalysis, we'd love to talk - we're actively supporting partners in this space.

Thanks for following our journey. You can always reach us on LinkedIn or contact the team directly. Exciting times ahead!